(Q34107940)

31 July 2017

1 reference

title

Fenretinide and cancer prevention (English)

1 reference

31 July 2017

Torrisi R

1

1 reference

PubMed ID

11122852

31 July 2017

Decensi A

series ordinal

2

1 reference

31 July 2017

1 May 2000

1 reference

31 July 2017

Current Oncology Reports

1 reference

31 July 2017

2

1 reference

31 July 2017

263-270

1 reference

31 July 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/s11912-000-0077-x

31 July 2017

0 references

cites work

Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-000-0077-X

Ocular effects of fenretinide, a vitamin A analog, in a chemoprevention trial of bladder cancer

21 January 2018

1 reference

12 December 2020

Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial.

1 reference

12 December 2020

Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms.

1 reference

12 December 2020

4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors

1 reference

12 December 2020

Effects of fenretinide (4-HPR) on dark adaptation

1 reference

12 December 2020

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

1 reference

12 December 2020

N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma

1 reference

12 December 2020

Induction of apoptosis by N-(4-hydroxyphenyl)retinamide and its association with reactive oxygen species, nuclear retinoic acid receptors, and apoptosis-related genes in human prostate carcinoma cells

1 reference

12 December 2020

Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point

1 reference

12 December 2020

Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients

1 reference

12 December 2020

In vitro interaction of fenretinide with plasma retinol-binding protein and its functional consequences

1 reference

12 December 2020

Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results

1 reference

12 December 2020

Evaluation of biomarker modulation by fenretinide in prostate cancer patients

1 reference

12 December 2020

Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin.

1 reference

12 December 2020

The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients

1 reference

12 December 2020

N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid

1 reference

12 December 2020

Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations

1 reference

12 December 2020

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually

1 reference

12 December 2020

Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer.

1 reference

12 December 2020

Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study

1 reference

12 December 2020

Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3.

1 reference

12 December 2020

Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate.

1 reference

12 December 2020

Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation

1 reference

12 December 2020

N-(4-Hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat

1 reference

12 December 2020

The insulin-like growth factor I receptor: a key to tumor growth?

1 reference

12 December 2020

Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients.

1 reference

12 December 2020

Retinoids and apoptosis: implications for cancer chemoprevention and therapy

1 reference

12 December 2020

Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids)

1 reference

12 December 2020

Circulating concentrations of insulin-like growth factor I and risk of breast cancer

1 reference

12 December 2020

Role of antioxidants and intracellular free radicals in retinamide-induced cell death.

1 reference

12 December 2020

Retinoids in the chemoprevention of bladder cancer

1 reference

12 December 2020

Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface

1 reference

12 December 2020

N-(4-hydroxyphenyl) retinamide is cytotoxic to melanoma cells in vitro through induction of programmed cell death

1 reference

12 December 2020

Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer

1 reference

12 December 2020

Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells

1 reference

12 December 2020

Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis.

1 reference

12 December 2020

Chemoprevention of breast cancer with fenretinide (4-HPR): study of long-term visual and ophthalmologic tolerability

1 reference

12 December 2020

Phase I/II trial of tamoxifen with or without fenretinide, an analog of vitamin A, in women with metastatic breast cancer

1 reference

12 December 2020

Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells

1 reference

12 December 2020

A decade of molecular biology of retinoic acid receptors

1 reference

12 December 2020

Can fenretinide protect women against ovarian cancer?

1 reference

12 December 2020

Carcinogenesis and cancer: different perspectives on the same disease

1 reference

12 December 2020

Cancer chemoprevention: progress and promise

1 reference

12 December 2020

Phase IIa study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an intermediate end point

1 reference

12 December 2020

Effects of chronic administration of N-(4-hydroxyphenyl)retinamide (4-HPR) in rats on vitamin A metabolism in the eye

1 reference

12 December 2020

Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.

1 reference

12 December 2020

Effect of retinoids on AOM-induced colon cancer in rats: modulation of cell proliferation, apoptosis and aberrant crypt foci.

1 reference

12 December 2020

Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamide

1 reference

12 December 2020

Clinical development plan: N-(4-hydroxyphenyl)retinamide

1 reference

12 December 2020

10.1007/S11912-000-0077-X

Identifiers

DOI

1 reference

PubMed ID

11122852

Dimensions Publication ID

31 July 2017

0 references

1 reference

PubMed ID

11122852